The stock of Neumora Therapeutics Inc. (NMRA) has gone down by -8.40% for the week, with a -22.91% drop in the past month and a -37.32% drop in the past quarter. The volatility ratio for the week is 7.26%, and the volatility levels for the past 30 days are 7.56% for NMRA. The simple moving average for the past 20 days is -24.36% for NMRA’s stock, with a -30.97% simple moving average for the past 200 days.
Is It Worth Investing in Neumora Therapeutics Inc. (NASDAQ: NMRA) Right Now?
There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for NMRA is 53.02M, and at present, short sellers hold a 9.28% of that float. The average trading volume of NMRA on April 25, 2024 was 535.79K shares.
NMRA) stock’s latest price update
Neumora Therapeutics Inc. (NASDAQ: NMRA) has seen a decline in its stock price by -6.89 in relation to its previous close of 10.30. However, the company has experienced a -8.40% decline in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-16 that The FDA places a clinical hold on Neumora’s (NMRA) phase I study evaluating NMRA-266 for some types of neuropsychiatric disorders. Shares of the company fall on the news.
Analysts’ Opinion of NMRA
Many brokerage firms have already submitted their reports for NMRA stocks, with Deutsche Bank repeating the rating for NMRA by listing it as a “Hold.” The predicted price for NMRA in the upcoming period, according to Deutsche Bank is $13 based on the research report published on December 12, 2023 of the previous year 2023.
William Blair, on the other hand, stated in their research note that they expect to see NMRA reach a price target of $26. The rating they have provided for NMRA stocks is “Outperform” according to the report published on October 10th, 2023.
Stifel gave a rating of “Buy” to NMRA, setting the target price at $26 in the report published on October 10th of the previous year.
NMRA Trading at -37.18% from the 50-Day Moving Average
After a stumble in the market that brought NMRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.33% of loss for the given period.
Volatility was left at 7.56%, however, over the last 30 days, the volatility rate increased by 7.26%, as shares sank -23.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -46.90% lower at present.
During the last 5 trading sessions, NMRA fell by -8.40%, in comparison to the 20-day moving average, which settled at $12.53. In addition, Neumora Therapeutics Inc. saw -43.75% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NMRA starting from Burow Kristina, who purchase 3,357 shares at the price of $11.98 back on Nov 14 ’23. After this action, Burow Kristina now owns 4,131,207 shares of Neumora Therapeutics Inc., valued at $40,217 using the latest closing price.
ARCH Venture Partners XII, LLC, the 10% Owner of Neumora Therapeutics Inc., purchase 3,357 shares at $11.98 during a trade that took place back on Nov 14 ’23, which means that ARCH Venture Partners XII, LLC is holding 4,131,207 shares at $40,217 based on the most recent closing price.
Stock Fundamentals for NMRA
The total capital return value is set at -0.43. Equity return is now at value -54.49, with -51.15 for asset returns.
Based on Neumora Therapeutics Inc. (NMRA), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -24.77.
Currently, EBITDA for the company is -135.28 million with net debt to EBITDA at 1.83. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.05.
Conclusion
In summary, Neumora Therapeutics Inc. (NMRA) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
